

Table 19.29  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2006-2012

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )			
Lymphoid Neoplasm	175,423	69.9 ( 69.6 , 70.1 )	90.1 ( 89.4 , 90.7 )	77.3 ( 77.0 , 77.7 )	59.4 ( 58.9 , 59.9 )				
1 Hodgkin Lymphoma	14,954	86.2 ( 85.6 , 86.9 )	96.9 ( 95.8 , 97.6 )	90.2 ( 89.5 , 90.9 )	54.3 ( 51.3 , 57.3 )				
2 Non-Hodgkin lymphoma	156,176	68.7 ( 68.4 , 69.1 )	88.2 ( 87.4 , 89.0 )	75.7 ( 75.3 , 76.1 )	60.1 ( 59.6 , 60.7 )				
2(a) Non-Hodgkin lymphoma, B-cell	144,111	69.1 ( 68.8 , 69.4 )	88.8 ( 87.8 , 89.6 )	76.5 ( 76.1 , 76.9 )	60.7 ( 60.1 , 61.2 )				
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	7,914	68.6 ( 67.4 , 69.8 )	88.4 ( 87.3 , 89.4 )	38.9 ( 36.5 , 41.3 )	17.3 ( 13.7 , 21.2 )				
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	129,173	69.2 ( 68.8 , 69.5 )	89.9 ( 87.8 , 91.7 )	78.0 ( 77.6 , 78.4 )	60.9 ( 60.4 , 61.5 )				
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	30,939	78.4 ( 77.6 , 79.1 )	- ( - , - )	86.7 ( 85.8 , 87.5 )	72.6 ( 71.5 , 73.7 )				
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	27,182	81.5 ( 80.7 , 82.3 )	- ( - , - )	89.6 ( 88.7 , 90.4 )	76.1 ( 74.9 , 77.2 )				
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	97	43.2 ( 29.8 , 55.9 )	- ( - , - )	52.8 ( 31.9 , 70.0 )	37.0 ( 20.6 , 53.6 )				
2(a) 2.1.3. Mantle-cell lymphoma	3,660	55.9 ( 53.6 , 58.1 )	- ( - , - )	68.3 ( 65.3 , 71.0 )	45.5 ( 42.2 , 48.6 )				
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,806	82.0 ( 79.4 , 84.4 )	- ( - , - )	89.8 ( 87.0 , 92.0 )	77.2 ( 73.3 , 80.6 )				
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,273	77.7 ( 73.6 , 81.2 )	- ( - , - )	85.3 ( 80.6 , 89.0 )	72.7 ( 66.8 , 77.8 )				
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,533	85.7 ( 82.1 , 88.6 )	- ( - , - )	93.2 ( 89.5 , 95.6 )	80.9 ( 75.5 , 85.2 )				
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	33,755	62.0 ( 61.3 , 62.6 )	88.3 ( 84.7 , 91.0 )	71.2 ( 70.4 , 72.0 )	52.5 ( 51.4 , 53.6 )				
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	33,322	61.8 ( 61.2 , 62.5 )	89.2 ( 85.6 , 91.9 )	71.1 ( 70.2 , 71.9 )	52.5 ( 51.4 , 53.6 )				
2(a) 2.3.2. Intravascular large B-cell lymphoma	54	51.3 ( 33.4 , 66.5 )	- ( - , - )	59.2 ( 35.1 , 76.9 )	44.2 ( 20.7 , 65.5 )				
2(a) 2.3.3. Primary effusion lymphoma	54	23.1 ( 11.6 , 37.0 )	- ( - , - )	23.8 ( 11.1 , 39.1 )	- ( - , - )				
2(a) 2.3.4. Mediastinal large B-cell lymphoma	325	83.9 ( 78.1 , 88.2 )	69.4 ( 43.8 , 85.1 )	86.8 ( 81.0 , 90.9 )	- ( - , - )				
2(a) 2.4. Burkitt lymphoma/leukemia	2,202	60.2 ( 57.9 , 62.4 )	89.7 ( 86.4 , 92.1 )	56.9 ( 53.9 , 59.7 )	36.4 ( 30.4 , 42.5 )				
2(a) 2.5. Marginal-zone lymphoma (MZL)	9,414	89.7 ( 88.5 , 90.8 )	98.5 ( 89.7 , 99.8 )	93.1 ( 91.9 , 94.2 )	86.3 ( 84.2 , 88.2 )				
2(a) 2.5.1. Splenic MZL	831	85.6 ( 80.8 , 89.2 )	- ( - , - )	85.6 ( 79.8 , 89.8 )	85.4 ( 78.1 , 90.4 )				
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	5,667	93.9 ( 92.4 , 95.1 )	97.8 ( 85.0 , 99.7 )	96.0 ( 94.6 , 97.0 )	91.6 ( 88.6 , 93.9 )				
2(a) 2.5.3. Nodal MZL	2,916	82.7 ( 80.3 , 84.8 )	- ( - , - )	88.9 ( 86.2 , 91.1 )	77.4 ( 73.6 , 80.7 )				
2(a) 2.6. Follicular lymphoma	17,971	87.5 ( 86.7 , 88.2 )	97.3 ( 80.1 , 99.7 )	91.7 ( 90.9 , 92.4 )	81.6 ( 80.0 , 83.1 )				
2(a) 2.7. Hairy-cell leukemia	1,511	92.6 ( 89.9 , 94.5 )	- ( - , - )	96.8 ( 94.6 , 98.1 )	81.4 ( 73.4 , 87.2 )				
2(a) 2.8. Plasma cell neoplasms	30,545	48.4 ( 47.6 , 49.2 )	- ( - , - )	61.4 ( 60.3 , 62.5 )	38.1 ( 37.1 , 39.2 )				
2(a) 2.8.1. Plasmacytoma	1,893	66.8 ( 63.7 , 69.6 )	- ( - , - )	77.9 ( 74.4 , 81.0 )	51.4 ( 46.0 , 56.4 )				
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	28,652	47.2 ( 46.4 , 48.0 )	- ( - , - )	60.0 ( 58.8 , 61.1 )	37.5 ( 36.4 , 38.6 )				
2(a) 2.9. Heavy chain disease	30	59.8 ( 34.0 , 78.3 )	- ( - , - )	- ( - , - )	- ( - , - )				
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	7,024	68.4 ( 66.8 , 70.0 )	92.7 ( 83.1 , 96.9 )	76.2 ( 74.1 , 78.1 )	63.2 ( 60.8 , 65.5 )				

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2006-2012

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	10,585	65.1 ( 63.9 , 66.2 )	86.5 ( 84.3 , 88.4 )	68.4 ( 67.0 , 69.7 )	51.4 ( 49.0 , 53.8 )				
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	498	66.1 ( 61.6 , 70.2 )	87.5 ( 82.6 , 91.1 )	50.1 ( 43.0 , 56.7 )	7.5 ( 1.3 , 21.2 )				
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	10,034	65.2 ( 64.0 , 66.3 )	86.2 ( 83.6 , 88.4 )	69.3 ( 67.9 , 70.7 )	52.1 ( 49.7 , 54.5 )				
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,507	90.1 ( 87.9 , 91.9 )	94.8 ( 76.6 , 98.9 )	92.1 ( 89.9 , 93.8 )	85.5 ( 79.6 , 89.8 )				
2(b) 2.1.1. Mycosis fungoides	2,429	91.7 ( 89.5 , 93.5 )	94.8 ( 76.6 , 98.9 )	93.0 ( 90.8 , 94.7 )	88.7 ( 82.5 , 92.8 )				
2(b) 2.1.2. Sezary syndrome	78	35.9 ( 21.2 , 50.8 )	- ( - , - )	47.8 ( 26.8 , 66.2 )	20.8 ( 4.6 , 44.8 )				
2(b) 2.2. Peripheral T-cell lymphoma	5,623	57.7 ( 56.0 , 59.2 )	83.6 ( 78.4 , 87.7 )	65.1 ( 63.2 , 67.0 )	43.5 ( 40.7 , 46.3 )				
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	1,928	38.9 ( 36.2 , 41.5 )	69.5 ( 52.3 , 81.6 )	46.0 ( 42.4 , 49.5 )	28.5 ( 24.4 , 32.6 )				
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	753	43.7 ( 39.3 , 48.0 )	- ( - , - )	55.4 ( 49.0 , 61.3 )	34.2 ( 28.3 , 40.2 )				
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	74	88.4 ( 76.9 , 94.4 )	- ( - , - )	88.8 ( 73.2 , 95.6 )	- ( - , - )				
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,145	59.6 ( 56.2 , 62.8 )	84.9 ( 78.1 , 89.7 )	65.0 ( 60.9 , 68.8 )	30.9 ( 23.8 , 38.2 )				
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	52	26.6 ( 14.4 , 40.5 )	- ( - , - )	29.0 ( 14.4 , 45.3 )	- ( - , - )				
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	59	13.2 ( 4.6 , 26.6 )	- ( - , - )	8.8 ( 0.9 , 28.3 )	16.6 ( 3.6 , 37.7 )				
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	1,088	83.8 ( 80.3 , 86.7 )	96.2 ( 75.5 , 99.5 )	88.1 ( 84.3 , 91.0 )	76.3 ( 70.0 , 81.4 )				
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	524	89.5 ( 84.5 , 93.0 )	- ( - , - )	95.1 ( 90.7 , 97.4 )	78.0 ( 65.1 , 86.6 )				
2(b) 2.3. Adult T-cell leukemia/lymphoma	1,210	62.0 ( 58.5 , 65.2 )	86.7 ( 83.4 , 89.4 )	41.0 ( 35.0 , 46.9 )	14.8 ( 7.4 , 24.7 )				
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	435	43.2 ( 37.6 , 48.7 )	- ( - , - )	43.4 ( 37.2 , 49.4 )	39.1 ( 26.3 , 51.6 )				
2(b) 2.5. T-cell large granular lymphocytic leukemia	99	68.8 ( 56.6 , 78.3 )	- ( - , - )	78.8 ( 62.7 , 88.5 )	57.8 ( 39.4 , 72.4 )				
2(b) 2.6. Prolymphocytic leukemia, T-cell	160	13.6 ( 7.1 , 22.4 )	- ( - , - )	18.3 ( 8.9 , 30.3 )	9.0 ( 1.9 , 22.9 )				
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	53	38.1 ( 24.8 , 51.4 )	- ( - , - )	51.0 ( 31.8 , 67.3 )	- ( - , - )				
2(c) Non-Hodgkin lymphoma, unknown lineage	1,480	59.4 ( 56.5 , 62.2 )	86.2 ( 82.1 , 89.4 )	57.5 ( 52.7 , 62.0 )	44.1 ( 39.1 , 49.0 )				
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	609	65.0 ( 60.9 , 68.8 )	86.5 ( 82.4 , 89.7 )	39.4 ( 31.1 , 47.6 )	21.7 ( 13.5 , 31.2 )				
2(c) 2. Prolymphocytic leukemia, unknown lineage	44	51.2 ( 34.1 , 66.0 )	- ( - , - )	- ( - , - )	42.2 ( 23.1 , 60.1 )				
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	827	55.6 ( 51.5 , 59.6 )	- ( - , - )	65.1 ( 59.4 , 70.3 )	48.3 ( 42.5 , 53.9 )				
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	9,021	68.3 ( 67.2 , 69.3 )	88.3 ( 87.3 , 89.3 )	40.1 ( 38.0 , 42.3 )	17.8 ( 14.6 , 21.3 )				
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	117	67.8 ( 55.4 , 77.5 )	- ( - , - )	77.9 ( 64.1 , 86.9 )	44.6 ( 20.8 , 65.9 )				
4 Lymphoid neoplasm, NOS <sup>c</sup>	4,176	50.0 ( 48.0 , 51.9 )	84.6 ( 73.2 , 91.4 )	61.9 ( 59.1 , 64.5 )	41.0 ( 38.3 , 43.7 )				

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.